Trials / Unknown
UnknownNCT04235179
Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer
Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer (ASPIRE)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- King Saud University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 30 Gy in 5 fractions, once weekly to the pelvis in post operative patients with endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | SABR | SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes) |
Timeline
- Start date
- 2020-01-16
- Primary completion
- 2022-01-01
- Completion
- 2026-01-01
- First posted
- 2020-01-21
- Last updated
- 2020-01-22
Locations
1 site across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT04235179. Inclusion in this directory is not an endorsement.